Portfolio Holdings Detail for ISIN IE00BYZK4776

Stock Name / Fund	iShares Healthcare Innovation UCITS ETF USD (Acc)
Issuer	Blackrock
Entity holding fund	iShares IV Public Limited Company
Entity Type	Umbrella investment company with variable capital and having segregated liability between its funds
Entity LEI	549300ZP07LMR36K1T02
ETF Ticker	DRDR(GBX) LSE
ETF Ticker	2B78(EUR) F
ETF Ticker	2B78.DE(EUR) CXE
ETF Ticker	DRDR.LS(GBX) CXE
ETF Ticker	HEAL.AS(EUR) CXE
ETF Ticker	HEAL.LS(USD) CXE
ETF Ticker	HEALz(USD) CXE
ETF Ticker	HEAL(EUR) ETF Plus
ETF Ticker	DRDR.L(GBP) LSE

Holdings detail for MRSN

Show aggregate MRSN holdings

News associated with MRSN

Mersana Therapeutics, Inc. (NASDAQ:MRSN) Receives $56.60 Average Target Price from Brokerages

Shares of Mersana Therapeutics, Inc. (NASDAQ:MRSN – Get Free Report) have been given a consensus rating of “Buy” by the six analysts that are presently covering the stock, MarketBeat reports. Six equities research analysts have rated the stock with a buy rating. The average 12-month price objective among brokers that have covered the stock in […] - 2025-08-27 02:07:07

Mersana Therapeutics, Inc. (NASDAQ:MRSN) Receives Average Rating of “Moderate Buy” from Brokerages

Shares of Mersana Therapeutics, Inc. (NASDAQ:MRSN – Get Free Report) have been given a consensus recommendation of “Moderate Buy” by the six ratings firms that are currently covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a hold recommendation and five have assigned a buy recommendation to the company. The average […] - 2025-07-30 02:30:59

Brokerages Set Mersana Therapeutics, Inc. (NASDAQ:MRSN) Price Target at $5.20

Mersana Therapeutics, Inc. (NASDAQ:MRSN – Get Free Report) has earned an average recommendation of “Buy” from the seven analysts that are currently covering the firm, MarketBeat.com reports. One analyst has rated the stock with a hold recommendation, five have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The […] - 2025-07-08 02:56:44

Brokerages Set Mersana Therapeutics, Inc. (NASDAQ:MRSN) Price Target at $5.20

Mersana Therapeutics, Inc. (NASDAQ:MRSN – Get Free Report) has earned an average recommendation of “Buy” from the seven analysts that are currently covering the firm, MarketBeat.com reports. One analyst has rated the stock with a hold recommendation, five have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The […] - 2025-07-08 02:21:48

Mersana Therapeutics, Inc. (NASDAQ:MRSN) Receives $5.20 Average Price Target from Brokerages

Shares of Mersana Therapeutics, Inc. (NASDAQ:MRSN – Get Free Report) have been given an average rating of “Buy” by the seven analysts that are covering the firm, MarketBeat Ratings reports. One investment analyst has rated the stock with a hold recommendation, five have assigned a buy recommendation and one has issued a strong buy recommendation […] - 2025-06-13 02:14:50

Bank of America Corp DE Has $1.36 Million Holdings in Mersana Therapeutics, Inc. (NASDAQ:MRSN)

Bank of America Corp DE cut its stake in Mersana Therapeutics, Inc. (NASDAQ:MRSN – Free Report) by 3.6% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 953,952 shares of the company’s stock after selling 36,084 shares during the quarter. Bank […] - 2025-06-06 04:34:57

Millennium Management LLC Boosts Stake in Mersana Therapeutics, Inc. (NASDAQ:MRSN)

Millennium Management LLC grew its position in shares of Mersana Therapeutics, Inc. (NASDAQ:MRSN – Free Report) by 206.4% during the fourth quarter, Holdings Channel reports. The fund owned 795,973 shares of the company’s stock after purchasing an additional 536,190 shares during the period. Millennium Management LLC’s holdings in Mersana Therapeutics were worth $1,138,000 as of […] - 2025-06-05 04:25:03

Short Interest in Mersana Therapeutics, Inc. (NASDAQ:MRSN) Increases By 21.4%

Mersana Therapeutics, Inc. (NASDAQ:MRSN – Get Free Report) was the target of a large increase in short interest during the month of May. As of May 15th, there was short interest totalling 12,780,000 shares, an increase of 21.4% from the April 30th total of 10,530,000 shares. Approximately 11.7% of the shares of the stock are […] - 2025-06-04 05:22:49

Mersana Therapeutics, Inc. (NASDAQ:MRSN) Shares Sold by Two Sigma Advisers LP

Two Sigma Advisers LP trimmed its position in shares of Mersana Therapeutics, Inc. (NASDAQ:MRSN – Free Report) by 8.0% in the fourth quarter, HoldingsChannel.com reports. The fund owned 448,000 shares of the company’s stock after selling 38,800 shares during the period. Two Sigma Advisers LP’s holdings in Mersana Therapeutics were worth $641,000 at the end […] - 2025-06-04 04:48:48

Deutsche Bank AG Sells 756,449 Shares of Mersana Therapeutics, Inc. (NASDAQ:MRSN)

Deutsche Bank AG cut its stake in Mersana Therapeutics, Inc. (NASDAQ:MRSN – Free Report) by 47.4% during the fourth quarter, HoldingsChannel reports. The fund owned 839,724 shares of the company’s stock after selling 756,449 shares during the quarter. Deutsche Bank AG’s holdings in Mersana Therapeutics were worth $1,201,000 as of its most recent SEC filing. […] - 2025-05-26 05:04:45

Mersana Therapeutics, Inc. (NASDAQ:MRSN) Receives Average Recommendation of “Buy” from Brokerages

Shares of Mersana Therapeutics, Inc. (NASDAQ:MRSN – Get Free Report) have been given a consensus rating of “Buy” by the seven analysts that are presently covering the firm, MarketBeat Ratings reports. One research analyst has rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy […] - 2025-05-21 05:09:00

Truist Financial Raises Mersana Therapeutics (NASDAQ:MRSN) Price Target to $10.00

Mersana Therapeutics (NASDAQ:MRSN – Free Report) had its price target lifted by Truist Financial from $9.00 to $10.00 in a research note issued to investors on Friday,Benzinga reports. They currently have a buy rating on the stock. MRSN has been the topic of several other reports. Guggenheim reissued a “buy” rating and issued a $5.00 […] - 2025-05-19 02:52:53

Barclays PLC Has $262,000 Holdings in Mersana Therapeutics, Inc. (NASDAQ:MRSN)

Barclays PLC cut its holdings in Mersana Therapeutics, Inc. (NASDAQ:MRSN – Free Report) by 63.1% during the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 182,711 shares of the company’s stock after selling 311,805 shares during the quarter. Barclays PLC’s holdings in Mersana Therapeutics were worth $262,000 at the end of the most recent reporting […] - 2025-05-12 04:30:56

Renaissance Technologies LLC Acquires 113,566 Shares of Mersana Therapeutics, Inc. (NASDAQ:MRSN)

Renaissance Technologies LLC lifted its holdings in shares of Mersana Therapeutics, Inc. (NASDAQ:MRSN – Free Report) by 23.0% during the 4th quarter, Holdings Channel reports. The firm owned 606,285 shares of the company’s stock after purchasing an additional 113,566 shares during the quarter. Renaissance Technologies LLC’s holdings in Mersana Therapeutics were worth $867,000 at the […] - 2025-05-02 05:54:49

XTX Topco Ltd Reduces Stock Holdings in Mersana Therapeutics, Inc. (NASDAQ:MRSN)

XTX Topco Ltd trimmed its position in Mersana Therapeutics, Inc. (NASDAQ:MRSN – Free Report) by 81.7% during the 4th quarter, HoldingsChannel reports. The firm owned 63,530 shares of the company’s stock after selling 283,725 shares during the period. XTX Topco Ltd’s holdings in Mersana Therapeutics were worth $91,000 as of its most recent filing with […] - 2025-04-30 05:31:04

ExodusPoint Capital Management LP Buys Shares of 194,153 Mersana Therapeutics, Inc. (NASDAQ:MRSN)

ExodusPoint Capital Management LP bought a new position in shares of Mersana Therapeutics, Inc. (NASDAQ:MRSN – Free Report) in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 194,153 shares of the company’s stock, valued at approximately $278,000. ExodusPoint Capital Management LP […] - 2025-04-14 04:46:54

Los Angeles Capital Management LLC Sells 29,900 Shares of Mersana Therapeutics, Inc. (NASDAQ:MRSN)

Los Angeles Capital Management LLC lowered its holdings in Mersana Therapeutics, Inc. (NASDAQ:MRSN – Free Report) by 15.8% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 159,760 shares of the company’s stock after selling 29,900 shares during the […] - 2025-03-05 08:46:57

Mersana Therapeutics, Inc. (NASDAQ:MRSN) Receives $5.57 Consensus Price Target from Analysts

Mersana Therapeutics, Inc. (NASDAQ:MRSN – Get Free Report) has earned an average rating of “Moderate Buy” from the nine brokerages that are covering the firm, MarketBeat reports. Two analysts have rated the stock with a hold recommendation, six have issued a buy recommendation and one has issued a strong buy recommendation on the company. The […] - 2025-02-19 04:12:53

China Universal Asset Management Co. Ltd. Buys Shares of 26,194 Mersana Therapeutics, Inc. (NASDAQ:MRSN)

China Universal Asset Management Co. Ltd. purchased a new stake in shares of Mersana Therapeutics, Inc. (NASDAQ:MRSN – Free Report) in the fourth quarter, according to its most recent 13F filing with the SEC. The fund purchased 26,194 shares of the company’s stock, valued at approximately $37,000. A number of other hedge funds have also […] - 2025-02-05 06:46:56

iShares Healthcare Innovation UCITS ETF USD (Acc) MRSN holdings

Share Trades of MRSN by Blackrock for IE00BYZK4776

Date	Action	Quantity	Market High	Market Low	Likely Trade Price	Likely Trade Value (Profit/Loss)	Average Price previous trades
2025-06-11	SELL	-716	9.500	10.750	10.625	USD -7,608	0.87 Loss of -6,982 on sale
2025-05-30	SELL	-716	8.600	9.000	8.960	USD -6,415	0.90 Loss of -5,769 on sale
2025-05-21	BUY	716	8.825	9.575	9.500	USD 6,802	0.93
2025-05-14	SELL	-4,302	9.500	9.550	9.545	USD -41,063	0.96 Loss of -36,951 on sale
2025-04-30	SELL	-718	10.825	11.050	11.028	USD -7,918	1.01 Loss of -7,194 on sale
2025-04-28	SELL	-718	9.600	9.825	9.802	USD -7,038	1.02 Loss of -6,306 on sale
2025-04-25	SELL	-718	9.100	9.300	9.280	USD -6,663	1.03 Loss of -5,927 on sale
2025-04-11	SELL	-4,320	7.775	7.825	7.820	USD -33,782	1.09 Loss of -29,065 on sale
2025-04-08	SELL	-2,160	7.325	8.425	8.315	USD -17,960	1.12 Loss of -15,548 on sale
2025-04-07	SELL	-1,442	7.625	8.275	8.210	USD -11,839	1.13 Loss of -10,216 on sale
2025-03-31	SELL	-1,442	8.600	9.500	9.410	USD -13,569	1.16 Loss of -11,897 on sale
2025-03-21	SELL	-1,444	10.625	11.375	11.300	USD -16,317	1.21 Loss of -14,569 on sale
2025-03-12	SELL	-722	12.750	12.975	12.953	USD -9,352	1.28 Loss of -8,431 on sale
2025-02-28	SELL	-722	13.075	13.200	13.187	USD -9,521	1.36 Loss of -8,539 on sale
2025-02-25	BUY	722	13.200	14.250	14.145	USD 10,213	1.40
2025-02-20	SELL	-722	13.200	14.225	14.123	USD -10,196	1.44 Loss of -9,160 on sale
2025-02-19	BUY	1,444	13.925	15.000	14.893	USD 21,505	1.45
2025-02-18	BUY	722	14.575	15.500	15.407	USD 11,124	1.46
2025-01-22	SELL	-722	13.200	13.750	13.695	USD -9,888	1.82 Loss of -8,576 on sale
2025-01-17	SELL	-722	15.475	15.675	15.655	USD -11,303	1.90 Loss of -9,928 on sale
2024-12-30	SELL	-1,372	35.500	37.250	37.075	USD -50,867	2.16 Loss of -47,901 on sale
2024-12-06	SELL	-660	63.250	63.750	63.700	USD -42,042	2.13 Loss of -40,639 on sale
2024-12-04	SELL	-662	56.750	60.000	59.675	USD -39,505	2.11 Loss of -38,106 on sale
2024-12-03	SELL	-1,332	59.250	63.500	63.075	USD -84,016	2.10 Loss of -81,213 on sale
2024-11-21	SELL	-707	49.500	57.250	56.475	USD -39,928	2.09 Loss of -38,452 on sale
2024-11-20	SELL	-723	55.500	58.750	58.425	USD -42,241	2.08 Loss of -40,737 on sale
2024-11-19	SELL	-723	55.500	56.000	55.950	USD -40,452	2.07 Loss of -38,954 on sale
2024-11-18	SELL	-2,724	52.750	57.250	56.800	USD -154,723	2.07 Loss of -149,086 on sale
2024-11-12	SELL	-679	55.000	63.125	62.313	USD -42,310	2.06 Loss of -40,911 on sale
2024-11-07	SELL	-681	63.750	66.500	66.225	USD -45,099	1.98 Loss of -43,748 on sale
2024-11-05	SELL	-1,364	50.250	51.000	50.925	USD -69,462	1.95 Loss of -66,803 on sale
2024-10-28	SELL	-686	51.000	51.750	51.675	USD -35,449	2.02 Loss of -34,061 on sale

Market high and low price is on the date.

* (if shown) = market close price used not a projected price. This is used when we do not have market data available to calculate a projection

The likely trade price/value is our estimate on the likely price the trade took place at and is not the actual trade price. The likely LOSS/GAIN is our estimate. Where a profit/loss value is shown in the Likely Trade Value column, this is derived from matching trades between periods eg the most recent previous BUY is matched with the SELL for the same number of shares and the difference between the likely BUY price and likely SELL price is calculated. Where a profit or loss is shown in the Average Price of Previous Trades column, this is dervied using the likely trade price compared to the average of previous trades based on adjusted close

Shorting History of MRSN

The data here is derived from FINRA daily shorted trade data. The Daily Short Sale Volume is the total volume of short trades that meet certain criteria on each trade date by 6 PM ET on the trade date. The detail trade data is derived from the monthly shorted trade data which will differ in aggregate. The detail trade data is derived from the transaction level data and includes ALL trades (including exempt) and the aggregation period extends beyond 6pm.

Back to Listing

Note: All information is provided as is without warranty and should be used for indicative purposes only. You should independently check data before making any investment decision. This information is derived from third party sources and we cannot guarantee that their data is current, accurate, complete, free from defects etc and we therefore accept no responsibility for how it may be used. We accept no liability.

Copyright Market Footprint Ltd. Privacy Policy